Meeting
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
Authors
P. J. Hesketh
Lahey Clinic, Tufts University School of Medicine, Burlington, MA
P. J. Hesketh , V. Moiseyenko , G. Rosati , A. Makhson , J. Levin , M. W. Russo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Supportive Care
Clinical Trial Registration Number
NCT00601172
Citation
J Clin Oncol 29: 2011 (suppl; abstr 9019)
Abstract #
9019
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2017 Gastrointestinal Cancers Symposium
Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.
First Author: Wenjing Wang
Poster
2018 ASCO Annual Meeting
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
First Author: Soniya Dulal
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).
First Author: Meinolf Karthaus